Industry-chain Research Brief

Beijing Kejian Biotechnology Co., Ltd.: Biomedicine Little Giant Industry Chain Brief

Beijing · Biomedicine · 2026-06-12

English company profile Full Chinese report All report summaries

English Summary

Beijing Kejian Biotechnology Co., Ltd. is a China Little Giant company report summary for overseas readers. The company is associated with Beijing. The report is indexed under Biomedicine. The Chinese report was published on 2026-06-12. The summary covers company profile, product direction, industry-chain role, technology, patent/R&D signals, scale indicators and policy-material checkpoints.

Report Snapshot

CompanyBeijing Kejian Biotechnology Co., Ltd.
RegionBeijing
IndustryBiomedicine
Published2026-06-12
Chinese reportOpen
CompanyBeijing Kejian Biotechnology Co., Ltd.
Region / IndustryBeijing · Biomedicine
Recognition2022 4th batch
Patent signal27 patent-related records

Company and Recognition Snapshot

Beijing Kejian Biotechnology Co., Ltd. is indexed as a national-level Little Giant enterprise in Beijing. The English profile places the company under Biomedicine and records 2022 4th batch as the available recognition context.

Recognition batch2022 4th batch
RegionBeijing
IndustryBiomedicine
Registered capitalRMB 11.00 million
Employee signal100-500人(中小企业参考) employees
Listed statusNot listed
Patent signal27 patent-related records
R&D signalR&D investment detail not published in the English dataset

Business and Industry-chain Position

Chinese public records indicate medical-device or biomedicine activity, R&D, design and engineering activity. The recorded industry-chain position is Biomedicine and medical devices / Recorded position. This places the company in a policy-relevant segment for peer comparison by region, industry and batch.

Technology, Patent and R&D Signals

The public profile records 27 patent-related records. The R&D signal is: R&D investment detail not published in the English dataset. Patent and R&D information should be read with product direction, customer evidence and chain position rather than as isolated threshold items.

Policy-material Review Points

  • Verify whether the company's main business, niche market and product evidence all point to Biomedicine.
  • Check that patent, R&D, employee and financial fields support the same core product direction.
  • Compare the company with peers in the same province, industry and recognition batch before using the profile for supplier screening or policy research.
  • Use the linked Chinese source report for original-language evidence and source links.

Original Report and Profile

For the underlying database record, open the English company profile. For full-length analysis, original-language wording and public evidence links, open the Chinese source report.

Related Search Paths